LoginSignup
RPR

Royalty Pharma

Stock
Stock
ISIN: GB00BMVP7Y09
Ticker: RPRX
GB00BMVP7Y09
RPRX

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

Royalty Pharma has so far distributed $0.817 in 2026. The next dividend will be paid on 10.12.2026

$0.86

CHART BY

Frequently asked questions

The market capitalization of Royalty Pharma is $26.01B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Royalty Pharma is 31.09. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Royalty Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.879. EPS indicates the company's profitability on a per-share basis.
Currently, 10 analysts cover Royalty Pharma's stock, with a consensus target price of $65.71. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Royalty Pharma reported a revenue of $2.54B.
Royalty Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.59B. EBITDA measures the company's overall financial performance.
Royalty Pharma has a free cash flow of $3.01B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Royalty Pharma employs approximately 100 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
The free float of Royalty Pharma is 417.05M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$26.01B
EPS (TTM) 
$1.879
Free Float 
417.05M
P/E ratio (TTM) 
31.09
Revenue (TTM) 
$2.54B
EBITDA (TTM) 
$1.59B
Free Cashflow (TTM) 
$3.01B

Pricing

1D span
$57.85$59.06
52W span
$34.64$64.38

Analyst Ratings

The price target is $65.71 and the stock is covered by 10 analysts.

Buy

8

Hold

2

Sell

0

Information

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Employees
100
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

ISIN
GB00BMVP7Y09
Primary Ticker
RPRX

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin